Johanna Mylet - Mar 1, 2023 Form 4 Insider Report for Poseida Therapeutics, Inc. (PSTX)

Role
Chief Financial Officer
Signature
/s/ Harry J. Leonhardt, Attorney-in-Fact
Stock symbol
PSTX
Transactions as of
Mar 1, 2023
Transactions value $
-$23,128
Form type
4
Date filed
3/2/2023, 05:28 PM
Previous filing
Mar 1, 2022
Next filing
Mar 4, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PSTX Common Stock Award $0 +92.8K +104.03% $0.00 182K Mar 1, 2023 Direct F1, F2
transaction PSTX Common Stock Tax liability -$23.1K -4.32K -2.38% $5.35 178K Mar 1, 2023 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PSTX Employee Stock Option (Right to Buy) Award $0 +125K $0.00 125K Mar 1, 2023 Common Stock 125K $5.35 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares issuable upon the vesting of restricted stock units granted pursuant to the Issuer's Equity Incentive Plan. The RSUs are scheduled to vest in four equal annual installments.
F2 Includes 3,000 shares acquired by the Reporting Person under the Issuer's 2020 Employee Stock Purchase Plan on March 18, 2022, and 1,951 shares acquired by the Reporting Person under the Issuer's 2020 Employee Stock Purchase Plan on September 20, 2022.
F3 Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a Restricted Stock Unit Award granted to the Reporting Person on March 1, 2022.
F4 12.5% of the shares subject to the stock option will vest and become exercisable on the six-month anniversary of the grant date listed in column 3 above, and the remaining shares will vest in 42 equal monthly installments thereafter.